European Society for Medical Oncology shared a post on LinkedIn:
“In the era of Precision Medicine, waiting lists for alteration-matched studies are one of the key challenges in Early Drug Development.
Findings presented at ESMOTATAsia25 highlighted that Patient Reported Outcomes (PROs) may be a valid tool to select fitness for inclusion in a phase I Clinical Trial after 3 months.
Also presented were recommendations from the OPTIMISE-ROR project, which provides foundational guidance for triallists to systematically integrate PROs into dose-finding oncology trials.
Read the full commentary in the ESMO Daily Reporter.”
More posts featuring ESMO on OncoDaily.